Business
OBD pursuing EpiSwitch as companion diagnostics
OBD pursuing EpiSwitch as companion diagnostics.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n\n\nOxford BioDynamics (\"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \nOxford Biodynamics to present on its line of EpiSwitch® products for companion diagnostics in cancer immunotherapy at the 14th World Summit for Clinical Biomarkers and Companion Diagnostics in Boston, MA.\nOxford, UK - 25 July 2024 - Oxford BioDynamics, Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on the EpiSwitch® 3D genomics platform [1], announces its key-note presentation at the 14th World Summit for Clinical Biomarkers and Companion Diagnostics, taking place on 3-6 September 2024 in Boston, MA, USA.\nOxford BioDynamics will discuss the diagnostic, predictive and prognostic power of the EpiSwitch® platform as companion assays in a keynote presentation. The Company will cover:\n· EpiSwitch CiRT, a highly accurate (85%) Immune-Oncology (IO) response test available today, predicts a patient's response to immune checkpoint inhibitor therapy, giving physicians a powerful tool for patient care management.\n· PROWES (Prospective Real-World Evidence Study); an application of CiRT in an IRB-approved Registry Study currently enrolling up to 2,500 patients across up to a dozen oncology institutions, evaluating CiRT performance and demonstrating the clinical utility of the test.\n· EpiSwitch® CiRT has been submitted to the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) for approval.\n· EpiSwitch® HiRT, a prognostic test for IO-triggered Hyperprogressive Disease, is a new test being validated by OBD to address this most detrimental and life-threatening side effect of immunotherapy.\n· Application of a novel multiplexed Agilent® array platform to deliver EpiSwitch® assays for early diagnosis and prevention of immune related adverse events (irAEs) which affect up to 70% of treated patients involving cutaneous, musculoskeletal, gastrointestinal, renal, nervous system, endocrine, hematologic and lung toxicities.\n \nOxford BioDynamics will present a keynote address at the 14th Annual World Summit for Clinical Biomarkers and Companion Diagnostics, a flagship meeting which takes place on Septem...